Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 4/20 | 0.76 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GAPDH | P04406 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HBB | P68871 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388256 | 0.91 | HSPA8 (0.62) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL23548003 | 0.91 | HSPA8 (0.62) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL28087475 | 0.91 | HSPA8 (0.62) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL30484790 | 0.90 | HSPA8 (0.61) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL5672368 | 0.89 | HSPA8 (0.60) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL5672193 | 0.89 | NADK (0.61) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL30237271 | 0.89 | HSPA8 (0.60) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL1740341 | 0.89 | NADK (0.61) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL30237449 | 0.89 | HSPA8 (0.60) | HSPA8HSPA5RXFP1HSD17B10GAPDH | |
| SCHEMBL30237237 | 0.89 | NADK (0.61) | HSPA8HSPA5RXFP1HSD17B10GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | claimed |
| EP-1539188-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | claimed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| EP-2399588-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. | 2007-11-29 | — | — | US | disclosed |
| US-7202224-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1539188-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3709/4885HSPA5 1811/4885RXFP1 4698/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | HSPA8 2731/4885HSPA5 1435/4885RXFP1 4822/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | HSPA8 3951/4885HSPA5 2044/4885RXFP1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.